Is 2045 the best we can do? Mitigating the HPV-related oropharyngeal cancer epidemic

Area of Science:

• Oncology
• Epidemiology
• Public Health

Background:

• Oropharyngeal cancer (OPC) incidence is projected to rise significantly by 2045, primarily driven by human papillomavirus (HPV) infections.
• Survivors of OPC often face long-term treatment complications and increased mortality.
• Current HPV vaccination strategies are insufficient for individuals already exposed to the virus.

Purpose of the Study:

• To analyze the projected incidence of HPV-related OPC in the U.S. through 2045.
• To evaluate the impact of current HPV vaccination rates on future OPC incidence.
• To explore the potential of targeted screening for early detection of HPV-related OPC.

Main Methods:

• Literature review of English-language articles on PubMed.
• Focus on incidence, screening, and prevention of HPV-related malignancies, specifically OPC in the U.S.

Main Results:

• HPV-related OPC incidence is expected to continue increasing in the near future.
• HPV vaccination will have a minimal effect on OPC rates until 2060 without a substantial increase in uptake.
• Targeted screening methods for early diagnosis are becoming increasingly feasible.

Conclusions:

• Urgent increases in HPV vaccination rates are necessary.
• Development of screening methods to identify high-risk individuals is critical.
• Early diagnosis through screening can lead to less morbid treatments and improved outcomes, bridging the gap until vaccination's full impact is realized.